ES2563777T3 - Compuestos de nitrona para tratar la pérdida auditiva sensorineural - Google Patents

Compuestos de nitrona para tratar la pérdida auditiva sensorineural Download PDF

Info

Publication number
ES2563777T3
ES2563777T3 ES10814226.6T ES10814226T ES2563777T3 ES 2563777 T3 ES2563777 T3 ES 2563777T3 ES 10814226 T ES10814226 T ES 10814226T ES 2563777 T3 ES2563777 T3 ES 2563777T3
Authority
ES
Spain
Prior art keywords
nitrona
hearing loss
compounds
sensorineural hearing
treat sensorineural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10814226.6T
Other languages
English (en)
Spanish (es)
Inventor
Richard Dana Kopke
Robert A. Floyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Hough Ear Institute
Original Assignee
Oklahoma Medical Research Foundation
Hough Ear Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, Hough Ear Institute filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of ES2563777T3 publication Critical patent/ES2563777T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endoscopes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES10814226.6T 2009-08-24 2010-08-24 Compuestos de nitrona para tratar la pérdida auditiva sensorineural Active ES2563777T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27411809P 2009-08-24 2009-08-24
US274118P 2009-08-24
PCT/US2010/046420 WO2011028503A1 (en) 2009-08-24 2010-08-24 Methods for treating acute acoustic trauma

Publications (1)

Publication Number Publication Date
ES2563777T3 true ES2563777T3 (es) 2016-03-16

Family

ID=43649578

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10814226.6T Active ES2563777T3 (es) 2009-08-24 2010-08-24 Compuestos de nitrona para tratar la pérdida auditiva sensorineural

Country Status (8)

Country Link
US (2) US10555915B2 (https=)
EP (1) EP2470015B1 (https=)
JP (2) JP5762414B2 (https=)
AU (1) AU2010289838C1 (https=)
CA (1) CA2772097C (https=)
ES (1) ES2563777T3 (https=)
IL (1) IL218302A (https=)
WO (1) WO2011028503A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3258955A1 (en) * 2015-02-20 2017-12-27 Institut Pasteur Prevention and/or treatment of hearing loss or impairment
US20180256756A1 (en) * 2015-09-18 2018-09-13 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
TWI642431B (zh) * 2016-10-28 2018-12-01 西德有機化學藥品股份有限公司 Ｎ－乙醯半胱胺酸用於治療突發性感覺神經性聽力損失的方法
US10576125B2 (en) * 2016-10-31 2020-03-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis
EP3570826A4 (en) * 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
JP6999896B2 (ja) 2017-09-21 2022-01-19 学校法人慶應義塾 音響外傷難聴モデル動物の作製方法及びそれにより作製される音響外傷難聴モデル動物
EP3787750A1 (en) * 2018-05-03 2021-03-10 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
US12121501B2 (en) 2018-09-12 2024-10-22 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
EP4309655A1 (en) * 2022-07-22 2024-01-24 Consejo Superior de Investigaciones Científicas (CSIC) Quinolylnitrone derivatives for use in the prevention and/or treatment of hearing loss

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6469049B1 (en) 2000-04-21 2002-10-22 The United States Of America As Represented By The Secretary Of The Army Method of treating, preventing or inhibiting central nervous system injuries and diseases
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
US7700111B2 (en) 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Auditory nerve protection and re-growth
WO2005016243A2 (en) * 2003-06-09 2005-02-24 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
TW200812567A (en) * 2006-03-29 2008-03-16 Kaneka Corp Agent for improving nervous system cell functions
JP5236641B2 (ja) * 2006-07-25 2013-07-17 ハフ イヤ インスティテュート 急性音響外傷の治療方法
BRPI0716143A2 (pt) * 2006-08-29 2013-11-26 Genentech Inc Uso de tenecteplase para tratar derrame isquêmico agudo
US20100234402A1 (en) * 2007-05-31 2010-09-16 Gideon Dreyfuss Methods and compositions for treating spinal muscular atrophy
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
KR20140069014A (ko) 2011-09-06 2014-06-09 사우스웨스트 나노테크놀로지스, 인크. 단일벽 탄소 나노튜브 정제 방법 및 개선된 단일벽 탄소 나노튜브

Also Published As

Publication number Publication date
JP6038233B2 (ja) 2016-12-07
EP2470015A4 (en) 2013-01-09
JP2015172071A (ja) 2015-10-01
JP5762414B2 (ja) 2015-08-12
JP2013502461A (ja) 2013-01-24
AU2010289838B2 (en) 2013-11-07
AU2010289838C1 (en) 2014-03-06
US20170224635A1 (en) 2017-08-10
CA2772097A1 (en) 2011-03-10
WO2011028503A1 (en) 2011-03-10
AU2010289838A1 (en) 2012-04-19
US20120172435A1 (en) 2012-07-05
IL218302A (en) 2017-02-28
EP2470015B1 (en) 2016-01-13
EP2470015A1 (en) 2012-07-04
CA2772097C (en) 2019-04-30
US10555915B2 (en) 2020-02-11
IL218302A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
ES2563777T3 (es) Compuestos de nitrona para tratar la pérdida auditiva sensorineural
ES2661582T3 (es) Efecto antiinflamatorio de la celulosa microfibrilada
ES2526555T3 (es) Composición fungicida y método para controlar enfermedades de plantas
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
CR20120296A (es) Nuevos compuestos de espiropiperidina
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
UY32062A (es) Inhibidores de beta-secretasa
CL2008000403A1 (es) Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
HN2011001446A (es) Compuesto utiles para inhibir chk1
ES2421442T3 (es) Métodos para repeler artrópodos utilizando isolongifolenona
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
CL2009001298A1 (es) Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4.
ECSP13013094A (es) Composiciones de limpieza de sal colina
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
ES2531516T3 (es) Uso de escina
ES2508165T3 (es) Lactoferrina y sustancia blanca
CO6400226A2 (es) Micrólido anti-inflamatorio
ES2529434T3 (es) Método para tratar neoplasias hematopoyéticas
ES2664171T3 (es) Aditivo retardador del fraguado y plastificante para el hormigón
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.